Deployment Psychology Blog

Staff Perspective: Sleep Disturbances and Suicide Risk

By Regina Shillinglaw  on 10.04.2019 1:51 pm

Relatively recent research has established sleep problems as an important predictor of elevated suicide risk. Specific aspects of sleep problems that are associated with greater suicide risk are not clear, but insomnia severity, insomnia duration, nightmare severity, and nightmare duration are possibilities. Since there are multiple dimensions of sleep that may play a role in suicide risk, more attention is needed to understand the mechanisms by which sleep influences one’s risk for suicide.

CDP News: 5 April 2019

By Christopher Adams  on 05.04.2019 11:40 am

Welcome to this week’s edition of CDP News! We like to use this space to review recent happenings in and around the Center for Deployment Psychology, while also looking ahead to upcoming events. April is here and we've got a wide selection of training ahead.

Research Update: 4 April 2019

By Shirl Kennedy  on 04.04.2019 10:35 am
Research Update icon

The weekly Research Update contains the latest news, journal articles, useful links from around the web. Some of this week's topics include:
● Benefits of sequentially adding cognitive-behavioral therapy or antidepressant medication for adults with nonremitting depression.
● Familial Aggregation and Coaggregation of Suicide Attempts and Comorbid Mental Disorders in Adults.
● CBT-I & subjective-objective sleep discrepancy.
● Sleep Regularity is Associated with Sleep-Wake and Circadian Timing, and Mediates Daytime Function in Delayed Sleep-Wake Phase Disorder.

Staff Perspective: Is Ketamine a Cure for Treatment-Resistant Depression?

By Paula Domenici  on 03.04.2019 10:06 am

On 5 March 2019, the US Food and Drug Administration (FDA) approved the nasal spray medication Spravato (esketamine) for treatment-resistant depression in adults. Some people are applauding this new medication as a much-needed shift from the era of antidepressants, including Prozac, Zoloft, and Paxil. “Finally, a drug that uses a different mechanism of action than these older antidepressants,” they cheer. Esketamine is a glutamate receptor modulator that is believed to help restore synaptic connections in a depressed person’s brain cells. Other critics are more skeptical, concerned it won’t be the panacea we’ve been looking for.

Pages